This concurrent resolution records legislative findings about Lyme disease and proclaims May 2025 as Lyme Disease Awareness Month. It compiles scientific and epidemiological statements—about transmission, clinical complexity, testing limits, coinfections, and the presence of Borrelia species in California—and urges awareness without creating new legal duties or funding.
The resolution matters because it elevates a public-health issue that the bill characterizes as underdiagnosed, potentially disabling, and geographically widespread in California. For professionals, the resolution is primarily a signal: it can catalyze local outreach, clinical vigilance, and stakeholder advocacy, but it does not itself allocate resources or change regulatory responsibilities.
At a Glance
What It Does
The bill is a concurrent resolution that records findings about Lyme disease and formally designates May 2025 as Lyme Disease Awareness Month. It includes detailed legislative recitals summarizing transmission, clinical presentation, testing limitations, coinfections, and regional tick data for California.
Who It Affects
The resolution speaks to public-health agencies, clinicians, patient and advocacy groups, outdoor workers and employers, and local governments that might choose to mount awareness campaigns. It imposes no statutory obligations on businesses or agencies.
Why It Matters
By compiling state-level findings and naming an awareness month, the Legislature creates a reference point for outreach and advocacy. The resolution can prompt local education efforts and media coverage but does not provide funding or require changes to clinical practice or surveillance systems.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The text is a ceremonial, fact-based statement rather than a law that creates duties or funding. Its recitals summarize what the Legislature cites as key facts: Lyme disease is caused by Borrelia bacteria and primarily transmitted by ticks; its early symptoms can mimic flu and rashes but untreated infection can progress to multisystem disease and long-term disability.
The resolution emphasizes diagnostic challenges—calling out unreliable testing and frequent misdiagnoses with conditions such as chronic fatigue, fibromyalgia, multiple sclerosis, and psychiatric disorders.
The bill cites national and state-specific epidemiology: a Centers for Disease Control and Prevention estimate of hundreds of thousands of U.S. cases per year, substantial proportions of patients with long-term problems, and regional variability in tick infection rates. It explains tick biology relevant to human risk (nymphal ticks are small and often go unnoticed) and identifies the western blacklegged tick as California’s principal vector, noting broad geographic presence in the state.Beyond Lyme itself, the recitals highlight complicating factors: ticks can carry multiple pathogens simultaneously (babesiosis, anaplasmosis, ehrlichiosis), and recent descriptions of additional Borrelia species have increased the set of organisms recognized in California.
Those points underscore both clinical complexity and surveillance gaps—areas where clinicians, public-health officials, and researchers may need clearer guidance and better diagnostics.The operative language is short and administrative: the Legislature adopts the findings and designates an awareness month. The resolution also instructs the Chief Clerk to transmit copies for distribution.
The document therefore functions as an official policy signal and source material for outreach, rather than as a vehicle for substantive policy change or funding allocations.
The Five Things You Need to Know
The Legislature’s recitals cite a CDC estimate of approximately 476,000 new Lyme disease cases in the United States per year.
The bill notes up to 40% of Lyme disease cases may result in long-term health problems, implying about 190,400 patients annually at risk of chronic issues.
The text records that the western blacklegged tick (Ixodes pacificus) has been found in 56 of California’s 58 counties.
The resolution reports that nymphal tick infection rates in some California areas have been measured as high as 42 percent.
The bill notes that three recently described Borrelia species increase the number of Lyme-complex spirochetes identified in California to five, complicating local pathogen ecology.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Legislative findings about Lyme disease and vectors
This section compiles the factual statements the Legislature considered: etiology (Borrelia spp.), clinical spectrum, diagnostic limitations, epidemiology, tick biology, coinfections, and new species identified in California. Practically, these recitals create a single, cited narrative the state can use in public messaging, grant applications, or to justify future policy proposals—but they do not themselves create authority to regulate or fund programs.
Designation of an awareness month (administrative, symbolic)
The operative text directs that May 2025 be proclaimed Lyme Disease Awareness Month. As a concurrent resolution, this action is ceremonial and nonbinding: it neither changes statutes nor imposes regulatory duties. The practical implication is reputational—the Legislature is signaling priority and providing official language localities or advocacy groups can reuse.
Distribution and filing formalities
A short closing clause instructs the Chief Clerk to transmit copies to the author for distribution and the bill shows it was filed with the Secretary of State (chaptered). The file notes no fiscal committee action, which aligns with the text’s lack of appropriations or mandates. Those formalities matter if entities seek to cite the resolution as enacted law or as background in funding requests or policy proposals.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People living with or at risk for Lyme disease and advocacy groups — the resolution raises public and clinician awareness, which can support earlier recognition, patient advocacy, and reduced stigma.
- Local public-health departments and county health officers — the official designation provides a timely justification to run outreach campaigns, secure partners, or amplify prevention messaging during May.
- Clinicians and school health personnel — increased attention may prompt quicker consideration of tick-borne illness in differential diagnoses and stimulate refresher training or guidance requests.
- Outdoor workers and employers (park staff, firefighters, landscapers) — the resolution legitimizes workplace prevention messaging and could be a trigger for employer-led education or protective policies (repellents, tick checks).
- Researchers and diagnostic labs — the legislative recitals call out surveillance and pathogen complexity, which can help justify research proposals or local studies to map tick infection rates.
Who Bears the Cost
- Local and county public-health agencies — while the resolution doesn’t appropriate funds, agencies that mount awareness or prevention activities will absorb personnel and outreach costs or must seek outside funding.
- Clinicians and health systems — increased public attention may generate demand for testing and consultations; managing that demand can increase provider time and lab utilization without guaranteed reimbursement changes.
- Employers of outdoor workers — if employers act on the resolution by instituting training, protective gear, or screenings, those are borne by the employers absent mandates.
- Clinical laboratories — a surge in testing driven by awareness can raise operational costs and squeeze turnaround times, particularly given the bill’s note that testing is imperfect and may prompt repeat tests or confirmatory work.
- Insurers and payers — greater testing and longer diagnostic workups could increase short-term claims related to diagnostic services, even though the resolution does not direct coverage changes.
Key Issues
The Core Tension
The central dilemma is between the clear public-health benefit of raising awareness (which can prompt prevention, earlier diagnosis, and support for affected people) and the risk that a symbolic proclamation, absent funding or diagnostic improvements, will generate unmet demand and encourage unproven testing or treatments—shifting scarce public-health and clinical resources without resolving the underlying surveillance and diagnostic gaps.
This is a symbolic instrument with practical consequences that are easy to overstate. By designating an awareness month and cataloguing scientific findings, the Legislature increases pressure on clinicians and public-health bodies to respond—but it provides no funding, no new reporting requirements, and no regulatory fixes for the diagnostic problems the text itself highlights.
That gap creates a risk that awareness drives demand (for tests, specialist visits, or long-term treatments) without improving the availability or accuracy of diagnostics and surveillance.
There is also a substantive tension the bill does not resolve: the recitals highlight both the need for early, appropriate treatment and the absence of a single, reliable diagnostic test. Elevating the issue without addressing testing standards could unintentionally fuel use of unvalidated diagnostics or long-term antibiotic prescriptions sought by patients.
Implementation questions are practical and procedural: who should coordinate statewide messaging, how to prioritize county responses where tick prevalence varies widely, and whether surveillance will be standardized to track the state-level claims the resolution quotes.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.